Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01400-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Chuhan Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, 100730, China. Hauptthemen laut MEDLINE: COVID-19, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Chinese National Key Technology R&D Program, Ministry of Science and Technology, Beijing Municipal Science & Technology Commission, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
The relationship between antiphospholipid syndrome (APS) and acute viral infection, such as SARS-CoV-2, is unclear. This study aims to assess symptoms, antiphospholipid antibody (aPL) fluctuations, and complication risks in APS patients infected with SARS-CoV-2. APS patients from Peking Union Medical College Hospital during the COVID-19 outbreak (October–December 2022) were included. Age- and gender-matched APS patients without infection served as controls. Data on demographics, symptoms, treatments, and serum aPL levels were analyzed. Of 234 APS patients, 107 (45.7%) were infected with SARS-CoV-2. Typical symptoms included high fever (81.3%), cough/expectoration (70.1%), and pharyngalgia (52.3%). Age- and gender-based matching selected 97 patients in either infected or uninfected group. After infection, anti-β-2-glycoprotein I-IgG (aβ2GP1-IgG) increased from 4.14 to 4.18 AU/ml, aβ2GP1-IgM decreased from 9.85 to 7.38 AU/ml, and anticardiolipin-IgA (aCL-IgA) significantly increased with a median remaining at 2.50 APLU/ml. Lupus anticoagulants and other aPLs remained stable. Arterial thrombosis incidence increased from 18 (18.6%) to 21 (21.6%), while venous thrombosis incidence did not change. Additionally, 7 (6.5%) patients presented either new-onset or worsening thrombocytopenia, characterized by a significant decline in platelet count (no less than 10 × 10 9 /L) within two weeks of SARS-CoV-2 infection, all of which recovered within 2 weeks. Acute SARS-CoV-2 infection may induce or worsen thrombocytopenia but does not substantially increase thrombotic events in APS. The process of SARS-CoV-2 infection was related to mild titer fluctuation of aβ2GP1-IgG, aβ2GP1-IgM and aCL-IgA in APS patients, necessitating careful monitoring and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, 100730, China.
- National Clinical Research Center of Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, 100730, China.
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, 100730, China.
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, 100730, China. 1084176048@qq.com.
- Department of Rheumatology and Immunology, Affiliated Qingyuan Hospital, The Sixth Clinical Medical School, Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, 511518, Guangdong, China. 1084176048@qq.com.
Förderung
- the Chinese National Key Technology R&D Program, Ministry of Science and Technology
- Beijing Municipal Science & Technology Commission
- CAMS Innovation Fund for Medical Sciences
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Wang, C., Jiang, H., Chen, S., Zhao, Y., Li, J., Huang, C., Zhou, Y., Wang, Q., Tian, X., Li, M., Zeng, X., Zhao, Y., Wu, C., & Zhao, J. (2024). Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01400-5
Vancouver
Wang C, Jiang H, Chen S, Zhao Y, Li J, Huang C, et al. Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01400-5
BibTeX
@article{Wang2024,
author = {Wang, Chuhan and Jiang, Hui and Chen, Siyun and Zhao, Yuan and Li, Jun and Huang, Can and Zhou, Yangzhong and Wang, Qian and Tian, Xinping and Li, Mengtao and Zeng, Xiaofeng and Zhao, Yan and Wu, Chuancong and Zhao, Jiuliang},
title = {Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01400-5}
}
EUVIMED